Question 1

How do CYP2C9 and CYP2C19 variants affect warfarin and clopidogrel dosing?

Accepted Answer

CYP2C9 loss-of-function variants impair warfarin metabolism, requiring lower doses to prevent excessive bleeding risk. CYP2C19 variants reduce clopidogrel activation, increasing thrombosis risk. These pharmacogenetics of phase I enzymes cytochrome P450 variations demonstrate how genetic differences in drug-metabolizing enzymes directly influence therapeutic dosing and safety profiles.

Question 2

What role do drug receptor polymorphisms play in treatment outcomes?

Accepted Answer

Drug receptor polymorphisms modify how drugs interact with their targets. TYMS polymorphisms with the 2R/2R genotype affect both toxicity and efficacy of anticancer agents. VKORC1 variants significantly alter warfarin dosing requirements, while variations in serotonin and β-adrenergic receptors influence responses to antidepressants and asthma medications respectively.

Question 3

How do MTHFR polymorphisms and ion channel variants affect drug safety?

Accepted Answer

MTHFR polymorphisms elevate homocysteine levels, increasing thrombosis risk. Ion channel variants in KCNQ1, KCNE1, and KCNE2 prolong baseline QT intervals, making individuals susceptible to drug-induced cardiac arrhythmias when using antiarrhythmics, macrolide antibiotics, or antihistamines. These biologic milieu modifications alter drug response independent of direct drug targeting.

Question 4

What is the relationship between CYP2D6 polymorphisms and opioid metabolism?

Accepted Answer

CYP2D6 polymorphisms significantly influence opioid metabolism and efficacy. Poor metabolizers experience reduced analgesic effects from codeine due to impaired activation, while ultrarapid metabolizers face morphine toxicity risks from excessive metabolism. These variations demonstrate how pharmacokinetic alterations affect drug concentration and clinical outcomes in pain management.

Question 5

How does UGT1A1 polymorphism affect irinotecan toxicity?

Accepted Answer

The UGT1A1 *28 polymorphism increases irinotecan toxicity by impairing glucuronidation, a phase II enzyme process essential for drug elimination. Patients with this variant require careful dose adjustments to prevent severe adverse effects. Understanding these genetic variations enables personalized medicine approaches that optimize drug efficacy while minimizing toxicity.

Question 6

How do genetic variations in coagulation-related genes influence thrombosis risk?

Accepted Answer

Variations in coagulation genes such as MTHFR, factor V, and prothrombin modulate thrombosis risk when prothrombotic drugs are used. These genetic polymorphisms alter the biologic milieu, affecting clotting cascade function. Identifying these variants guides therapeutic strategies and dosage adjustments, ensuring safer treatment plans for patients at elevated thrombosis risk.

Question 7

Why is identifying genetic variants important for personalized medicine?

Accepted Answer

Genetic variants influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Identifying these variants enables clinicians to predict drug efficacy and adverse effects, guiding dosage adjustments and therapeutic strategies. This personalized approach optimizes treatment outcomes while minimizing harm, making precision medicine essential for safer and more effective clinical care.

Farmakogenetik Fenotipler: Farmakokinetik, İlaç Hedefleri ve Biyolojik Ortamdaki Değişimler

Browse More Videos